10.07.24 -- Outsourced Complex Protein Development Demands Special Considerations

This webinar will focus on how KBI Biopharma's SUREtechnology Platform™, powered by Selexis®, enables rapid advancement of new complex biologics from early development to first-in-human (FIH). Register to learn how the integration of the SUREtechnology Platform™ accelerates the creation of high-performing, stable cell lines tailored for biologics production. Learn more here.

When functions such as analytics or formulation get outsourced, team dynamics must adapt to ensure cohesive integration and effective communication.

Analytical Method Development is a critical phase in development, and its implementation is essential for delivering high-quality products to market efficiently and effectively.

Testing vaccines is a rigorous multi-stage process. From initial lab research to human trials and regulatory approval, discover how vaccines undergo scrutiny to protect public health.

Discover how an experienced CDMO offering a purpose-built facility with flexible capacity can help biopharmaceutical companies bring their products to market quickly and efficiently.

By leveraging the expertise of CDMOs, pharmaceutical firms can expedite their time to market, reduce costs, and improve patient outcomes, advancing the future of drug delivery methods.

Explore important initial steps to consider and implement during the process design phase which is a pre-requisite to a successful PPQ campaign and readiness for commercial manufacturing.

Explore how the widespread adoption of autoinjectors is transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety.

This poster reviews studies for three monoclonal antibody drug candidates utilizing a panel of small scale, fast, and predictive tests used to evaluate therapeutic antibodies’ developability.

If you’re looking to work with a CDMO that can help you save money and ensure efficiency in your therapeutic production, consider the benefits of choosing a Polish partner.

Uncover the necessary components of a tech transfer for LNP-based drugs, including the outsourcing strategies needed to avoid pitfalls.

Clarification using depth filtration is standard in monoclonal antibody (mAb) manufacturing. Here, we showcase the scalability of Stax™ mAx depth filters, demonstrating their effectiveness.

Join the next Outsourced Pharma Live as our panel explores the critical considerations and best practices for selecting and managing CDMOs in the development of novel therapies, including advanced therapy medicinal products like cell and gene therapies. Industry experts will share insights on evaluating CDMO capabilities, ensuring quality and compliance, and fostering effective partnerships to accelerate innovation while mitigating risks.

The BD UltraSafe Plus passive needle guard for pre-filled ISO standard glass syringes is designed to support viscous drug delivery with ergonomics and drug visibility.

Our multi-product manufacturing facilities feature state-of-the-art equipment for animal cell-derived viral and microbial products for your clinical trials, following cGMP guidelines.

By streamlining the synthesis pathways, see how these products can effectively diminish the requisite number of developmental and manufacturing stages essential for generating payloads.

Our suite of analytical testing services for antibody-based drugs encompasses feasibility studies, method development, validation, routine testing, and stability assessments.

Finding a CDMO committed to increasing capacity and optimizing processes with innovative technologies is key to adding efficiency while maintaining high quality standards.